Sustainable leadership [5]
论文作者:匿名论文属性:短文 essay登出时间:2009-06-07编辑:刘宝玲点击率:29761
论文字数:10000论文编号:org200906071555332443语种:英语 English地区:中国价格:免费论文
关键词:SustainableleadershipManagementcontrolsystems
t control systems and organizational culture by unfolding Novo Nordisk's long-term commitment to sustainable business practices and the company's validations of these practices by focusing on how issues of sustainability are integrated and cascaded throughout the entire organization via the company's "Way of Management". The rest of the paper is structured as follows. The next section provides an introduction to Novo Nordisk and how sustainability is currently, and has been for a number of years, an integral part of its business. It also describes how Novo Nordisk meets its sustainability objective by describing the general management control systems in place. The following section then suggests the addition of a cultural perspective to understand the leadership of sustainability. The final section provides a critical analysis of management control systems and suggests integration of cultural dimensions in the assessment of sustainable business practices.
Introduction to Novo Nordisk A/S
Novo Nordisk A/S was founded in 1922 by a Danish Nobel laureate in physiology. Today, Novo Nordisk is a world leader in diabetes care and focus entirely on health care; the company also holds a leading position in hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk headquarters is located in Denmark, on the outskirts of Copenhagen, and employs approximately 20,000 employees in 78 countries. Novo Nordisk markets its products in 179 countries.
Figure 1 [Figure omitted. See Article Image.] shows Novo Nordisk's current organizational structure. From 2002 Corporate Stakeholder Relations became part of the executive management team along with R&D, Finance and Operations.
Novo Nordisk is a company based on research. Research and development expenditures equalled 43.2 percent of the total wage costs in 2004 and have been in the range of 15.0-16.6 percent of total turnover over the period 2000-2004. During this same period, Novo Nordisk had between 526 and 778 active patent families, with between 85 and 145 new patent families per year[1] . The share ownership of Novo Nordisk ensures that the organization has a high degree of freedom, as it is not open for takeovers, for example, from larger pharmaceutical companies.
Novo Nordisk's board of directors consists of ten members: seven elected by the shareholders and three by the employees[2] . Novo Nordisk's six executive directors as well as the directors of the Novo Nordisk Foundation are not represented in the Novo Nordisk board, which is in accordance with the general guidelines of corporate governance at the Copenhagen, London and New York stock exchanges. It has become an increasingly important issue to demonstrate that Novo Nordisk is doing business according to these guidelines.
Sustainability as principle
Novo Nordisk's vision is to "be the world's leading diabetes care company"[3] . A key principle to achieve the vision is Novo Nordisk's values and commitment to environmentally and socially responsible business conduct in all organizational practices.
Novo Nordisk has worked strategically with environmental and social responsibility for more than a decade, and today sustainability is an integrated part of the business strategy. Engagement in stakeholder dialogue and sustainability is extremely important to Novo Nordisk, and the company believes that the Triple Bottom Line is imperative, as CEO Lars Rebien Sørensen and Chairman Steen Scheibye
本论文由英语论文网提供整理,提供论文代写,英语论文代写,代写论文,代写英语论文,代写留学生论文,代写英文论文,留学生论文代写相关核心关键词搜索。